Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

The following is a summary of “Completed suicide in patients with skin disease: A systematic review and meta-analysis,” ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral ...

MoonLake Immunotherapeutics (MLTX) stock gains as RBC Capital Markets starts with outperform rating, citing $2B+ sales ...

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

US biotech Incyte (Nasdaq: INCY) has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 ...

Leerink analyst Andrew Berens notes that Outperform-rated Incyte (INCY) has reported the results of the two parallel Phase 3 trials evaluating ...

Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.